肿瘤分级可预测甲状腺髓样癌切除术后降钙素倍增时间及疾病特异性结局
这项回顾性分析纳入1986至2017年间在单一三级癌症中心接受手术的117例甲状腺髓样癌(MTC)患者,其中95例低级别、22例高级别,中位随访70.2个月。高级别患者降钙素倍增时间显著快于低级别患者(8.51±3.22个月 vs 38.42±11.19个月,p<0.001),且多变量分析显示高级别与更差的局部区域无复发生存(HR 4.77)、无远处转移生存(HR 7.25)和总生存(HR 6.04)相关。作者建议对高级别肿瘤患者进行密切监测。
要点
- 高级别MTC患者降钙素倍增时间显著快于低级别患者(8.51±3.22个月 vs 38.42±11.19个月,p<0.001)。
- 66.7%的高级别患者降钙素倍增时间小于1年,而低级别患者仅1.0%(p<0.001)。
- 多变量分析中,高级别患者局部区域无复发生存(HR 4.77)、无远处转移生存(HR 7.25)和总生存(HR 6.04)均显著更差。
核心结论
- 大多数高级别MTC患者降钙素倍增时间小于2年。
- 作者建议对评估为高级别肿瘤的患者进行密切监测,因其存在不良疾病特异性结局和结构性复发风险。
研究设计与样本
- 回顾性分析1986年至2017年间在单一三级癌症中心接受手术的MTC患者。
- 共纳入117例患者,其中95例为低级别,22例为高级别。
- 高级别MTC定义为两位头颈病理学家识别出核分裂指数≥5/2 mm²、肿瘤坏死或瘤内Ki67增殖指数≥5%。
- 降钙素倍增时间使用经验证的计算器计算,要求至少连续三次降钙素水平。
- 采用Cox比例风险模型评估局部区域无复发生存(LRFS)、无远处转移生存(DMFS)和总生存(OS)。
主要发现
- 高级别患者降钙素倍增时间显著快于低级别患者(8.51±3.22个月 vs 38.42±11.19个月;p<0.001)。
- 66.7%的高级别患者降钙素倍增时间小于1年,而低级别患者为1.0%(p<0.001)。
- 在降钙素倍增时间小于2年的患者中,70%为高级别,30%为低级别(p<0.001)。
- 多变量分析比较分级和降钙素倍增时间:高级别患者LRFS显著更差(HR 4.77 [CI 1.19-8.81]),DMFS显著更差(HR 7.25 [CI 2.36-22.28]),OS显著更差(HR 6.04 [CI 1.85-19.72];所有p<0.05)。
- 降钙素倍增时间小于2年与更差的DMFS相关(HR 7.22 [CI 1.05-49.75])。
关键数值与推荐
- 高级别MTC判定标准:核分裂指数≥5/2 mm²、肿瘤坏死或Ki67增殖指数≥5%。
- 降钙素倍增时间小于2年为先前验证的预后截断值。
临床怎么用
- 作者建议对评估为高级别肿瘤的患者进行密切监测,因其存在不良疾病特异性结局和结构性复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Tumor grade is a new validated prognostic factor for medullary thyroid cancer (MTC). Calcitonin doubling time can predict MTC recurrence. We aimed to describe the association of tumor grade with calcitonin doubling and its effect on disease-specific outcomes times after resection. Methods: A retrospective analysis of MTC patients who underwent resection at a single tertiary-care cancer center between 1986 and 2017 were evaluated. Tumors were designated as high-grade MTC if two head and neck pathologists identified mitotic index ≥5 per 2 mm2, tumor necrosis, or a Ki67 proliferative index ≥5% within the tumor. Calcitonin doubling time was calculated using a validated calculator with at least three consecutive levels. Using Cox proportional hazards models, outcomes evaluated included locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS). Results: Among 117 patients, 95 were low grade and 22 high grade. Median follow-up was 70.2 months. High-grade patients demonstrated significantly faster calcitonin doubling times when compared with low-grade patients (8.51 ± 3.22 months vs. 38.42 ± 11.19 months; p < 0.001). In addition, most high-grade patients (66.7%) had calcitonin doubling times less than 1 year compared with fewer low-grade patients (1.0%; p < 0.001). High- and low-grade patients were further stratified by those who had calcitonin doubling times less than or greater than 2 years-a previously validated prognostic cutoff point. For patients with calcitonin doubling times less than 2 years, 70% were high grade, while 30% were low grade (p < 0.001). On multivariate analysis comparing grade and calcitonin doubling times, high-grade patients had significantly worse LRFS (hazards ratio [HR] 4.77 [confidence interval; CI 1.19-8.81]), DMFS (HR 7.25 [CI 2.36-22.28]), and OS (HR 6.04 [CI 1.85-19.72]; p < 0.05 for all), while calcitonin doubling times less than 2 years had worse DMFS (HR 7.22 [CI 1.05-49.75]). High-grade patients with calcitonin doubling times less than 2 years had associated worse LRFS and OS (both p < 0.05) compared with low-grade patients. Conclusions: The majority of high-grade MTC patients have calcitonin doubling times less than 2years. Close monitoring should be advocated for patients assessed to have high-grade tumors as they are at risk for poor disease-specific outcomes and structural recurrence.
引用
- Nigam A, Xu B, Spanheimer PM, et al. Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma. Thyroid. 2022. PMID: 35950622. doi:10.1089/thy.2022.0217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。